Exclusivity period for biologics

Obama believes that biologics should be able to face competition after seven years on the market instead of 12-14.

Nancy-Ann DeParle, director of the Office of Health Reform, and Peter Orszag, director of the Office of Management and Budget wrote a letter to Rep. Henry Waxman stating

"Lengthy periods of exclusivity will harm patients by diminishing innovation and unnecessarily delaying access to affordable drugs."

Read the full article here.

If you're interested in networking with other professionals in the field of Biosimilars, join our LinkedIn Group here.

Share this article with your social network, just click below to share now!

Share |